Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label sorafenib study in previously treated advanced renal cell carcinoma
2005-002524-34Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sorafenib in renal cell carcinoma (RCC), sponsored by Bayer. Primary endpoint: Collection of additional safety data. Started Aug 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2005-002524-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002524-34.